Article
Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
Surgery - 1 Jun 2006
de Groot J W B, Plaza Menacho I, Schepers H, Drenth-Diephuis L J, Osinga J, Plukker J Th M, Links Th P, Eggen B J L, Hofstra R M W
Abstract excerpt
BACKGROUND: Activating mutations in the RET gene, which encodes a tyrosine kinase receptor, often cause medullary thyroid carcinoma (MTC). Surgical resection is the only curative treatment; no effective systemic treatment is available. We evaluated imatinib, a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.